Chennai-based pharmaceuticals major Orchid Chemicals & Pharmaceuticals Ltd has received approval from the Food and Drug Administration (FDA) of the US for its infectious diseases drug.
The company said in a release Friday that the FDA has approved its abbreviated new drug application for Cefpodoxime Proxetil tablets.
Abbott’s Low-dose Antiretroviral for Children Receives FDA Approval
Abbott Laboratories on Monday announced that it has received FDA approval to market and sell a lower-dose version of its antiretroviral drug Kaletra for children
Advertisement
The product is available in two dosage strengths of 100 mg and 200 mg.
Cefpodoxime Proxetil is a third-generation cephalosporin antibiotic, which has broad-spectrum activity against organisms causing infectious diseases.
With limited generic competition in this product, Orchid hopes to garner a sizeable market share and revenues in the US market, the company said Friday.
Source: IANS
MED/P
With limited generic competition in this product, Orchid hopes to garner a sizeable market share and revenues in the US market, the company said Friday.
Source: IANS
MED/P
US FDA Approves Osteoporosis Drug for Breast Cancer, but With Warnings
The US Food and Drug Administration approved Eli Lilly's Evista, an osteoporosis drug, for prevention of breast cancer, but the drug will also carry a boxed warning against risks of stroke.
Advertisement
 Activists Suspect FDA-Drug Industry NexusUS FDA is coming under increasing pressure over the problems posed by the drugs it approves. Activists plead for greater transparency. | Advertisement
|
Advertisement
Recommended Readings
Latest Drug News
The psychedelic market set for remarkable growth, projected to hit $7.2B by 2029 with a strong 55% CAGR.
The study explores whether CDNF could influence the progression of ALS in rodent models and to elucidate the mechanism through which it operates.
Amoxicillin-clavulanate use in acute sinusitis patients is associated with a higher incidence of adverse events.
Professionals advocate for enhanced education of patients and caregivers, and creation of more effective child-resistant systems for monitoring ADHD medication.
In June, WHO raised concerns about 7 Indian cough syrups after complaints from several countries about contamination and health issues.
